CLAIMS

1. Cells (I) having a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fucosyltransferase 7 (Fut-7) expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, the cells being for use in treating inflammation in a subject, the cells (I) being non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers, wherein, prior to administration of the cells (I) to the subject, the cells are assayed for having the desired potency.

2. The cells for the use of claim 1 wherein the cells are allogeneic.

3. The cells for the use of any one of claims 1-2 wherein the subject is human.

4. A method for constructing a cell bank, the method comprising expanding and storing, for future administration to a subject, cells (I) that have a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, the cells (I) being non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers, wherein the cells (I) are assayed for having the desired potency.

5. An *in vitro* method for drug discovery, the method comprising exposing cells (I) that have a desired potency for one or more of the following: 1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, to an agent to assess the effect of the agent on the ability of the cells to effect one or more of (1) – (4) above, the cells (I) being non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

6. The method of claim 5 wherein the cells (I) are assayed for having the desired potency.

7. A composition comprising non-embryonic stem, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal,

TSC PDF 1123167

ectodermal, and mesodermal germ layers, the cells having a potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fut-7 expression on a leukocyte, (4) reduce expression of CD15s on a leukocyte, wherein the potency is at a level higher than in the parental cell population.

8. The method of any one of claims 4-6, wherein adhesion is of E-selectin and/or P-selectin to CD15s.

9. The method of any one of claims 4-6, and 8 wherein the leukocyte is a lymphocyte.

10. The method of claim 9, wherein the lymphocyte is a $CD4^+$ or $CD8^+$ lymphocyte.

11. The method of any one of claims 4-6, and 8 wherein the leukocyte is a neutrophil.

12. The cells of any one of claims 1-3 and 7, wherein adhesion is of E-selectin and/or P-selectin to CD15s.

13. The cells of any one of claims 1-3 and 7, wherein the leukocyte is a lymphocyte.

14. The cells of claim 13, wherein the lymphocyte is a $CD4^+$ or $CD8^+$ lymphocyte.

15. The cells of any one of claims 1-3 and 7, wherein the leukocyte is a neutrophil.

16. The method of any one of claims 4-6, wherein the cells (I) are derived from bone marrow.

17. The composition of claim 7 wherein the cells (I) are derived from bone marrow.

18. The cells of any one of claims 1-3 and 7 wherein the cells (I) express telomerase.

19. The cells of any one of claims 1-3, 7 and 18 wherein the cells (I) express oct4.

20. The cells of any one of claims 1-3, 7 and 18-19 wherein the cells (I) express telomerase and oct4.

21. The cells of any one of claims 1-3, 7 and 18-20 wherein the cells (I) can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

TSC PDF 1123167

22. The cells of any one of claims 1-3, 7 and 18-21 wherein the cells (I) can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

23. The cells of any one of claims 1-3, 7 and 18-22 wherein the cells (I) express telomerase and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

24. The cells of any one of claims 1-3, 7 and 18-23 wherein the cells (I) express telomerase and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

25. The cells of any one of claims 1-3, 7 and 18-24 wherein the cells (I) express oct4 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

26. The cells of any one of claims 1-3, 7 and 18-25 wherein the cells (I) express oct4 and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

27. The cells of any one of claims 1-3, 7 and 18-26 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

28. The cells of any one of claims 1-3, 7 and 18-27 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

29. The cells for the use of any one of claims 1-3, 7 and 18-28 wherein the cells (I) are derived from bone marrow.

30. The cells for the use of any one of claims 1-3, 7 and 18-29 wherein the cells (I) are human cells.

31. The method of any of claims 4-6 wherein the cells (I) express telomerase.

32. The method of any of claims 4-6 and 31 wherein the cells (I) express oct4.

33. The method of any of claims 4-6 and 31-32 wherein the cells (I) express telomerase and oct4.

34. The method of any of claims 4-6 and 31-33 wherein the cells (I) can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

35. The method of any of claims 4-6 and 31-34 wherein the cells (I) can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

36. The method of any of claims 4-6 and 31-35 wherein the cells (I) express telomerase and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

37. The method of any of claims 4-6 and 31-36 wherein the cells (I) express telomerase and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

38. The method of any of claims 4-6 and 31-37 wherein the cells (I) express oct4 and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

39. The method of any of claims 4-6 and 31-38 wherein the cells (I) express oct4 and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

40. The method of any of claims 4-6 and 31-39 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

41. The method of any of claims 4-6 and 31-40 wherein the cells (I) express telomerase and oct4, and can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

42. The method of any one of claims 4-6 and 31-41 wherein the cells (I) are human cells.

TSC PDF 1123167